Astrazeneca Oxford Coronavirus Vaccine
- All
- News
- Videos
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
-
Clotting Linked With AstraZeneca Vaccine Very Rare, Says Oxford Study
The very rare blood clots that can be caused by the Oxford/AstraZeneca coronavirus vaccine can be aggressive and deadly but is very rare, leading scientists have concluded in the findings of the first study of its kind on Thursday.
-
Two Doses Mostly Prevent Hospitalisation With Delta Variant: UK Body
Two doses of COVID-19 vaccines are "highly effective" in preventing hospital admission with the Delta variant, Public Health England said on Monday.
-
Britain Seeks Extra AstraZeneca Shots To Combat "Beta" COVID-19 Variant
Britain is in talks with Oxford and AstraZeneca for additional doses of their COVID-19 vaccine that has been modified to better target the "beta" coronavirus variant first identified in South Africa, and it will fund trials of the shots.
-
Even Single Vaccine Dose Cuts COVID-19 Infection Rate, New UK Study Finds
A single dose of either the Oxford/AstraZeneca or Pfizer/BioNTech vaccines, currently being administered in the UK, cut the rate of coronavirus infections by around 65 per cent, according to a new UK study on Friday.
-
AstraZeneca UK Vaccine Trial On Children Paused As Clot Link Probed
A British trial of the AstraZeneca coronavirus vaccine on children has been paused while regulators assess its possible link to blood clots, Oxford University, which helped develop the jab, said Tuesday.
-
Italy To Restart AstraZeneca Vaccinations From Friday, Says PM
Italy will resume administering AstraZeneca/Oxford coronavirus vaccines on Friday after the EU's drugs regulator declared them safe, Prime Minister Mario Draghi said.
-
Oxford Study Shows AstraZeneca Shot Works Against Brazil Strain: Report
Preliminary data from a study conducted at the University of Oxford indicates that the COVID-19 vaccine developed by AstraZeneca PLC is effective against the P1, or Brazilian, variant, a source with knowledge of the study told Reuters on Friday.
-
Germany To Recommend Oxford Covid Vaccine For Over 65s: Angela Merkel
Germany will soon authorise the AstraZeneca/Oxford vaccine against Covid for people over the age of 65, Chancellor Angela Merkel said Wednesday.
-
Sri Lanka May Not Use China Vaccine, Orders 13.5 Million Doses From India
Sri Lanka has ordered 13.5 million Oxford AstraZeneca coronavirus vaccines in addition to the 500,000 doses gifted by India, and the country may not use Chinese vaccines in the second phase of immunisation, a government spokesman said today.
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
-
Clotting Linked With AstraZeneca Vaccine Very Rare, Says Oxford Study
The very rare blood clots that can be caused by the Oxford/AstraZeneca coronavirus vaccine can be aggressive and deadly but is very rare, leading scientists have concluded in the findings of the first study of its kind on Thursday.
-
Two Doses Mostly Prevent Hospitalisation With Delta Variant: UK Body
Two doses of COVID-19 vaccines are "highly effective" in preventing hospital admission with the Delta variant, Public Health England said on Monday.
-
Britain Seeks Extra AstraZeneca Shots To Combat "Beta" COVID-19 Variant
Britain is in talks with Oxford and AstraZeneca for additional doses of their COVID-19 vaccine that has been modified to better target the "beta" coronavirus variant first identified in South Africa, and it will fund trials of the shots.
-
Even Single Vaccine Dose Cuts COVID-19 Infection Rate, New UK Study Finds
A single dose of either the Oxford/AstraZeneca or Pfizer/BioNTech vaccines, currently being administered in the UK, cut the rate of coronavirus infections by around 65 per cent, according to a new UK study on Friday.
-
AstraZeneca UK Vaccine Trial On Children Paused As Clot Link Probed
A British trial of the AstraZeneca coronavirus vaccine on children has been paused while regulators assess its possible link to blood clots, Oxford University, which helped develop the jab, said Tuesday.
-
Italy To Restart AstraZeneca Vaccinations From Friday, Says PM
Italy will resume administering AstraZeneca/Oxford coronavirus vaccines on Friday after the EU's drugs regulator declared them safe, Prime Minister Mario Draghi said.
-
Oxford Study Shows AstraZeneca Shot Works Against Brazil Strain: Report
Preliminary data from a study conducted at the University of Oxford indicates that the COVID-19 vaccine developed by AstraZeneca PLC is effective against the P1, or Brazilian, variant, a source with knowledge of the study told Reuters on Friday.
-
Germany To Recommend Oxford Covid Vaccine For Over 65s: Angela Merkel
Germany will soon authorise the AstraZeneca/Oxford vaccine against Covid for people over the age of 65, Chancellor Angela Merkel said Wednesday.
-
Sri Lanka May Not Use China Vaccine, Orders 13.5 Million Doses From India
Sri Lanka has ordered 13.5 million Oxford AstraZeneca coronavirus vaccines in addition to the 500,000 doses gifted by India, and the country may not use Chinese vaccines in the second phase of immunisation, a government spokesman said today.
